publications

Colorectal cancer

Developing a digital twin framework for colorectal cancer outcome prediction and robust clinical trial simulation

Acute Myeloid Leukemia

STREAMLINE - Retrospective cohort study of FMS-like tyrosine kinase 3-mutated acute myeloid leukemia: Real-world treatment patterns and clinical outcomes of patients in first relapse or refractory diagnosis

Lung cancer

Patients with advanced non-small cell lung cancer harboring MET alterations: A descriptive cohort study

Acute Myeloid Leukemia

(PB2488) Chart review study on the real-world cytopenia management of patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents

Myelodysplastic syndrome

(PB2779) Chart review study on dose modifications of patients with myelodysplastic syndrome treated with hypomethylating agents

leukemia

Comparison of outcomes for patients (pts) with R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with Bruton tyrosine kinase inhibitor (BTKi) and venetoclax from the TRANSCEND CLL 004 study versus a matched cohort of real-world (RW) pts

Lung cancer

Identification of predictive subphenotypes for clinical outcomes using real world data and machine learning

Prostate cancer

Treatment patterns and survival by race among men with metastatic castration-resistant prostate cancer (mCRPC) in the United States: A US electronic medical record database 2020-2023

Prostate cancer

Real-world treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC) who previously progressed from metastatic hormone-sensitive prostate cancer (mHSPC) between 2020 to 2023 in the United States

Lung cancer

Biomarker testing and patterns of treatment in NSCLC patients: An IASLC analysis of ASCO CancerLinQ Discovery data

Bladder cancer

Practice patterns and outcomes of conventional versus split-dose cisplatin in neoadjuvant ddMVAC in bladder cancer

Prostate cancer

Survival outcomes among metastatic castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitor and docetaxel

Prostate cancer

Clinical use and outcomes of androgen-receptor pathway inhibitors triplet therapy for metastatic hormone-sensitive prostate cancer (ARAAT)

Breast cancer

Survival impact of adjuvant chemotherapy regimens for small (T1mi/a/b), node-negative (pN0), triple-negative breast cancer (TNBC)

other

Leveraging real-world data sources for clinical oncology research: A review of studies published in ASCO publications

other

Analysis of ASCO clinical guidelines authorship and institutional representation using HemOnc.org

Lung cancer

Real-world side effects of targeted therapies: High-throughput association studies leveraging the CancerLinq Discovery lung cancer database

Lung cancer

CO125: Adjusted comparison of amivantamab in combination with carboplatin plus pemetrexed from the PAPILLON study versus US real-world frontline treatments in patients with advanced NSCLC harboring EGFR exon 20 insertions

Bladder cancer

HSD64: Real-world adjuvant nivolumab utilization in surgically treated muscle-invasive bladder cancer patients within U.S. community oncology practice

Bladder cancer

Recurrence and its association with overall survival (OS) in muscle-invasive bladder cancer (MIBC) patients undergoing radical cystectomy (RC): A real-world analysis

Prostate cancer

Post-metastasis survival of patients with high-risk localized and locally advanced prostate cancer undergoing primary treatment in the United States: A retrospective study

Lung cancer

Prognostic score models for acquired resistance to frontline anti-programmed cell death protein 1/programmed death-ligand 1 therapy in metastatic non-small-cell lung cancer

Multiple tumor types

P32: Oncology trial emulation using real-world electronic health record data: Results of the Coalition to Advance Real-World Evidence through Randomized Controlled Trial Emulation (CARE) initiative

Lung cancer

Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study

Breast cancer

Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: A real-world evidence study

Colorectal cancer

Epidemiology of MET gene mRNA expression in metastatic colorectal cancer: Analyses of a real-world clinicogenomic database

Bladder cancer

Patterns of concurrent chemotherapy selection in US patients undergoing trimodality therapy for muscle-invasive bladder cancer

Renal cell carcinoma

Real world evidence comparison of first-line (1L) immune-oncology(IO)/tyrosine kinase inhibitor (TKI) vs. IO/IO combination therapy in renal cell carcinoma (RCC)

Multiple tumor types

6638 / 19 - Identifying cancer germline variants associated with patient prognosis and response by applying clinico-genomics data

Lung cancer

3395 / 15 - Investigating clinical features and molecular mechanisms of long-term response and acquired resistance to immunotherapy in non-small cell lung cancer by applying real-world-data

Prostate cancer

Survival outcomes of apalutamide as a starting treatment: Impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS)

Pediatric cancers

Pediatric cancer in the United States: A comparison of three data sources

Lung cancer

656P Real-world (RW) frontline (1L) treatments (Txs) in patients (Pts) with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EFGR) exon 20 insertions (exon20ins) and adjusted comparisons versus PAPILLON study

Prostate cancer

The value of integrating urology and oncology real-world data for understanding prostate cancer management

Multiple tumor types

Real-world use of accelerated approval oncology drugs subsequently withdrawn in the United States

Lung cancer

Comparing traditional NLP methods and LLM-based extraction for identifying biomarkers in lung cancer

Melanoma

Electronic health records (EHR)-based machine learning (ML) approach to predict risk of progression to metastatic melanoma after initial diagnosis

other

Machine learning model to forecast patient availability for oncology clinical trials

other

RWD116: Training and validation of CARAai™: A multi LLM platform and data model to address oncology-specific challenges in clinical data extraction

Other

EPH131: Estimating US cancer prevalence with community oncology EHR-based datasets via national benchmarks from SEER and NPCR

other

Behavior of test specificity under an imperfect gold standard: Findings from a simulation study and analysis of real-world oncology data

Colorectal cancer

Real-world clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with trifluridine-tipiracil + bevacizumab by performance status

other

Real-world patient characteristics and treatment patterns among cholangiocarcinoma patients treated with FGFR inhibitors

other

Leveraging large language models to drive efficiency in clinical trial simulation

Colorectal cancer

Real-world clinical outcomes of trifluridine-tipiracil monotherapy (FTD-TPI) and FTD-TPI + bevacizumab combination therapy (FTD-TPI+bev) in 639 black patients (pts) with metastatic colorectal cancer (mCRC)

Colorectal cancer

Real-world clinical outcomes of patients (pts) with metastatic colorectal cancer (mCRC) who received trifluridine-tipiracil (FTD-TPI) monotherapy or FTD-TPI + bevacizumab (FTD-TPI+bev) combination therapy

Chronic Lymphocytic Leukemia

Real-world effectiveness of frontline treatments among patients with chronic lymphocytic leukemia: Results from ConcertAI

Gastric

Biomarkers of response in patients with gastric/gastroesophageal junction adenocarcinoma (GEA) treated with telisotuzumab adizutecan

Ovarian cancer

Folate receptor alpha (FRα; FOLR1) expression and persistence in ovarian cancer in clinical trial samples and real-world patient cohort

Lung cancer

Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors

Prostate cancer

Racial disparities in clinical trial enrollment among patients diagnosed with prostate cancer: A population-based cohort of oncology practices

Prostate cancer

Clinical characteristics and treatment of patients with small cell prostate cancer: Analysis of a real-world cohort from an oncology database

Breast cancer

P1-09-09: Disparities in second breast cancer events and survival persist despite optimal treatment in hormone-receptor positive breast cancer: Analysis of the real-world ASCO CancerLinQ dataset

Breast cancer

P3-03-12: Social determinants of health (SDOH) and Z code utilization among patients with breast cancer (BC)

Breast cancer

P1-08-09: Real-world outcomes comparing 3-monthly with monthly goserelin implant in premenopausal women with breast cancer

Lung cancer

Evaluation of treatment strategies for patients with stage IIIA non-small cell lung cancer in the immunotherapy era

Prostate cancer

Real-world treatment and clinical outcomes in patients with metastatic castration-resistant prostate cancer treated with olaparib in the United States

Myelodysplastic syndrome

5189 Real-world use patterns and clinical outcomes for myelodysplastic syndrome patients initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents

other

4437 Real-world treatment patterns in patients with mycosis fungoides or Sezary syndrome treated with mogamulizumab in the United States: A retrospective database analysis

Chronic Lymphocytic Leukemia

4623 Mutations in the Bruton tyrosine kinase (BTK) gene in patients with chronic lymphocytic leukemia (CLL) receiving BTK inhibitors (BTKis)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Lung cancer

EP.11A.08 Real-world comparative effectiveness in advanced NSCLC and high PD-L1 with 1L immune checkpoint inhibitors ± chemotherapy

Lung cancer

Real-world clinical outcomes among patients with non-squamous advanced non-small cell lung cancer (aNSCLC) treated with docetaxel-based regimens post initial standard of care (SOC) in the United States

Breast cancer

245P - Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis

Lung cancer

1303P - METPRO: Evaluating prognostic value of c-Met protein overexpression and concurrent biomarker presence

Lung cancer

1352P - Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy

Lung cancer

Calibrating observational health record data against a randomized trial

other

Emulations of oncology trials using real-world data: A systematic literature review

Breast cancer

Real-world treatment patterns and outcomes in patients with HR+/HER2− metastatic breast cancer treated with chemotherapy in the United States

Prostate cancer

Treatment intensification in metastatic hormone-sensitive prostate cancer: An analysis of real-world practice patterns from the CancerLinQ Database

Multiple tumor types

RWD23 Addition of open administrative claims significantly improves capture of mortality in electronic health record (EHR) - focused real-world data (RWD)

Lung cancer

Evaluation of real-world tumor response derived from electronic health record data sources: A feasibility analysis in mNSCLC patients treated with chemotherapy

Lung cancer

194: Immune-related adverse events of anti-PD-(L)1 immunotherapy with and without chemotherapy in patients with advanced non-small cell lung cancer: A real-world evidence study

Breast cancer

1361: Quantification of information gained by linking claims data to an EHR cohort of US metastatic breast cancer (mBC) patients

Lung cancer

435: Identifying the period of heightened risk for adrenal insufficiency in patients with advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors

Pediatric cancers

1433: Pediatric cancer in the United States: A comparison of two data sources

Lung cancer

803: Representativeness of race, ethnicity and social determinants of health in patients with advanced non-small cell lung cancer via linkage of real-world electronic health records, administrative claims, and consumer financial data

N/A - psoriasis

1231: Unlocking insights: Lesson learned from the tokenization of a psoriasis trial

Lung cancer

242: A combined machine learning and natural language processing approach to determine metastatic date through integrated temporal modeling

Lung cancer

A retrospective analysis of treatment patterns, overall survival, and real-world disease-free survival in early-stage non-small cell lung cancer following complete resection

Other

Seeking American Society of Clinical Oncology-QualityOncology Practice Initiative (ASCO-QOPI) certification in anorthern New England rural health system and cancer care network

Ovarian cancer

Prognosis and conditional survival among women with newly diagnosed ovarian cancer

Breast cancer

Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer

Breast cancer

The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer

Lung cancer

EGFR mutation testing, treatment and survival in stage I–III non-small-cell lung cancer: CancerLinQ Discovery database retrospective analysis

Breast cancer

Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States

Follicular lymphoma

Assessing feasibility of using RWD to support biosimilar development: Rituximab use in US patients with follicular lymphoma

Lung cancer

Comparing prospectively assigned trial and real-world lung cancer patients

Prostate cancer

Rapid and deep prostate-specific antigen (PSA) response to apalutamide plus ADT and survival in metastatic castration-sensitive prostate cancer (mCSPC) in real world practice in the US (OASIS Project)

Lung cancer

A real-world study on biomarker retesting among patients with non-small cell lung cancer and disparity in outcomes

Lung cancer

Representativeness of race, ethnicity and social determinants of health in patients with advanced non-small cell lung cancer via linkage of real-world electronic health records, administrative claims, and consumer financial data

Renal cell carcinoma

Real-world study on the characteristics, post-nephrectomy journey, and outcomes of patients with early-stage renal cell carcinoma based on risk groups

Breast cancer

Electronic clinical quality measure (eCQM) concordance and quality care disparities among patients with breast cancer (BC)

Breast cancer

Disparities in patients with HER2-positive breast cancer receiving optimal treatment: Analysis of the real-world ASCO CancerLinQ dataset

Pancreatic cancer

Predicting real-world overall survival for post-operative pancreatic ductal adenocarcinoma: An ASCO CancerLinQ Discovery analysis

Prostate cancer

Real-world baseline treatment patterns and overall survival (rwOS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in the United States

Multiple myeloma

Dynamic machine learning model to forecast patient availability for clinical trials

Multiple myeloma

A prospective study comparing AI-based clinical trial eligibility screening with traditional EMR-based screening

Multiple myeloma

Efficient site selection for clinical trials using simulated annealing

Breast cancer

Abstract PO1-17-07: Invasive disease-free survival as a surrogate for overall survival in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative early breast cancer: a real-world analysis

Renal cell carcinoma

MP51-18 Population-based trends and outcomes for cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States

Prostate cancer

MP31-17 Variation in genomic testing amongst localized prostate cancer patients undergoing radical prostatectomy or radiation therapy: Results from a population-based cohort

Chronic Lymphocytic Leukemia

Retrospective electronic health records study in the CancerLinQ Discovery database of treatment patterns among patients with chronic lymphocytic leukemia

Chronic Lymphocytic Leukemia

Retrospective electronic medical records study of treatment patterns among CLL patients in the CancerLinQ research database

Other

Improving cancer data interoperability: The promise of the minimal Common Oncology Data Elements (mCODE) initiative

Other

Development of CancerLinQ, a health information learning platform from multiple electronic health record systems to support improved quality of care

Multiple tumor types

Summary of the 12 most common cancers in the CancerLinQ Discovery (CLQD) database

Other

Chasm between cancer quality measures and electronic health record data quality

other

Quantitating and assessing interoperability between electronic health records

Breast cancer

Real-world outcomes in metastatic HR+/HER2-, HER2+ and triple negative breast cancer after start of first-line therapy

Lung cancer

Retrospective analysis of real-world management of EGFR-mutated advanced NSCLC, after first-line EGFR-TKI treatment: US treatment patterns, attrition, and survival data

Multiple tumor types

Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 and Subsequent Mortality in a Multisite Cohort of Patients With Cancer in the CancerLinQ Discovery Database

Multiple Tumor Types

Challenges and opportunities to developing a frailty index using electronic health record data

Other

Cancer registry data linkage of electronic health record data from ASCO's CancerLinQ: Evaluation of advantages, limitations, and lessons learned

Breast cancer

Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2− MBC in the real world

Breast cancer

Survival in the real world: A national analysis of patients treated for early-stage breast cancer

other

Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

Lung cancer

The RESECT study: Factors associated with overall survival (OS) and relapse-free survival (RFS) among patients with stages I–III resected NSCLC without known EGFR mutations

Multiple myeloma

Pitfalls with analyses of real-world data: A look at ASCO’s CancerLinQ Discovery multiple myeloma dataset

Renal cell carcinoma

Uptake and efficacy of immuno-oncology combinations in metastatic renal cell carcinoma in the United States: Evidence from the ASCO CancerLinQ Discovery database

Colorectal cancer

Implementing a BRAF biomarker electronic clinical quality measure in CancerLinQ

Other

Case studies for overcoming challenges in using big data in cancer

Other

Challenges to using big data in cancer

Lung cancer

Evaluation of cost-effectiveness of adjuvant osimertinib in patients with resected EGFR mutation-positive non-small cell lung cancer

Multiple myeloma

Real-world big-data: Strengths and weaknesses of ASCO's CancerLinQ® discovery multiple myeloma dataset

Other

Health data sharing perspectives of patients receiving care in CancerLinQ-participating oncology practices

Multiple myeloma

Multiple myeloma in adolescent and young adults: An ASCO CancerLinQ and SEER analysis

Multiple myeloma

Prognostic impact of second primary malignancies in multiple myeloma: An ASCO CancerLinQ discovery analysis of the modern era

Multiple myeloma

Real-world pitfalls of analyzing real-world data: A cautionary note and path forward

Lung cancer

Natural history and real-world treatment outcomes for non-small cell lung cancer patients with EGFR Exon 20 Insertion Mutation: An IASLC- ASCO CancerLinQ Study

Lung cancer

Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer

Lung cancer

An emulation of the KEYNOTE-189 trial using electronic health records

other

Budget impact of pirtobrutinib for patients with mantle cell lymphoma (MCL) or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in the United States (US)

Prostate cancer

Comparative analysis of different methods of disease progression data capture in patients with metastatic castration-resistant prostate cancer

Lung cancer

Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer

other

Proportional randomization method to identify index line of therapy in externally controlled trials

Lung cancer

Integrating real-world histopathological and clinicogenomic data from 1799 lung cancer patients by applying unsupervised deep learning

Lung cancer

Harness the power of real-world-data for oncology target and biomarker research: A case study by applying clinic-genomics data for 2,659 lung cancer patients and beyond

Lung cancer

EP.12A.03 Overall survival after treatment with first-line osimertinib for EGFR-mutant advanced NSCLC in the US

Pancreatic cancer

KRAS co-mutational landscape dictates treatment outcomes in pancreatic cancer (PC) patients

Breast cancer

Identifying the genetic basis for resistance to aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients

Prostate cancer

Survival outcomes of APA as a starting treatment: Impact in real-world patients with mCSPC (OASIS)

Prostate cancer

Real-world homologous recombination repair mutation (HRRm) testing patterns in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in the United States

Gastric

Real-world treatment patterns, testing patterns, and clinical outcomes of first-line (1L) therapy for metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (mGC/GEJC/EAC)

Lung cancer

Predicting progression-free survival (PFS) in first-line (1L) immune checkpoint inhibitor (ICI)-treated patients (pts) with advanced non-small cell lung cancer (aNSCLC): Machine learning (ML) application in real-world data

Lung cancer

Identifying co-mutational signatures in STK11 mutated advanced non-small cell lung cancer (aNSCLC) patients that help overcome poor response to immune checkpoint inhibitors (ICI’s)

Multiple myeloma

Real-world progression-free survival and treatment patterns for t(11;14) positive patients with multiple myeloma with at least 2 prior lines of treatment

Other

Real-world treatment patterns and healthcare resource utilization in patients with Waldenström macroglobulinemia initiating first-line treatment with ibrutinib or zanubrutinib

Myelodysplastic syndrome

MDS-567 Real-world analysis of a large electronic medical record database of patients with higher-risk myelodysplastic neoplasms (HR MDS): Treatment profiles, clinical effectiveness, and key adverse event rates

Breast cancer

Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative (HR+/HER2−) early breast cancer (EBC): A US database analysis

Melanoma

Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients

Lung cancer

Adverse events and clinical outcomes in patients treated with PD-(L)1 blockade for advanced non-small-cell lung cancer

Multiple myeloma

Abstract A131: Clinical characteristics and outcomes of Black patients with multiple myeloma compared with other races

Prostate cancer

Post-metastasis survival in high-risk localised and locally advanced prostate cancer patients undergoing primary treatment in the United States: A retrospective study

Lung cancer

Clinical and economic impact of recurrence in early-stage non-small-cell lung cancer following complete resection

Lung cancer

Real-world treatment patterns and outcomes of patients with metastatic nonsquamous non-small cell lung cancer after progression on standard-of-care therapy in the United States

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

269 Impact of ibrutinib dose reduction on duration of therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Prostate cancer

Machine learning (ML) on real-world data (RWD) of front-line (1L) metastatic castration resistance prostate cancer (mCRPC) patients for dynamic prediction of time to tx discontinuation (TTD)

Lung cancer

19P Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis

Multiple myeloma

Augmentation of real-world mortality data in the electronic medical record: Assessing the impact on overall survival estimates in multiple myeloma

Lung cancer

573P LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets

Multiple tumor types

Site of metastasis (SoM) and its impact on clinical outcomes in 8 cancer cohorts

Lung cancer

Development of natural language processing (NLP) models for extracting key features from unstructured notes to create real-world data (RWD) assets for clinical research at scale

other

Enhancement in line of therapy (LoT) derivation from real-world data (RWD) from electronic health records (EHR) via integration of medical claims data

Lung cancer

An adjusted treatment comparison comparing amivantamab versus real-world clinical practice in Europe and the United States for patients with advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations

other

Supporting the use of RWD in oncology drug development, Session 1: Establishing a framework for evaluating real-world response

Prostate cancer

Comparative effectiveness of abiraterone and enzalutamide in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): A retrospective cohort study in a large database of deeply curated EHR real-world data (RWD) from community oncology practices in the US

Melanoma

Improving real-world mortality data quality in oncology research: Augmenting electronic medical records with obituary, Social Security Death Index, and commercial claims data

Lung cancer

957 Machine learning (ML) model for prediction of pneumonitis using real-world data (RWD) on immune checkpoint inhibitor (ICI)-treated advanced non-small cell lung cancer (aNSCLC)

Multiple myeloma

3358 Real-world evaluation of outcomes in relapsed/refractory multiple myeloma patients that are triple-class exposed after receiving 2 or more prior lines of therapy

Myelodysplastic syndrome

5100 Machine learning approach to understand real-world treatment in patients with higher-risk myelodysplastic syndromes

Chronic Lymphocytic Leukemia

5143 Impact of real-world treatment sequencing patterns on time to next treatment among patients with chronic lymphocytic leukemia in the United States

Large B-Cell Lymphoma

Racial and ethnic representation in large B-cell lymphoma trials and real-world databases

Lung cancer

Machine learning (ML) model for prediction of pneumonitis using real-world data (RWD) on immune checkpoint inhibitor (ICI)-treated advanced non-small cell lung cancer (aNSCLC)

Colorectal cancer

Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)

Breast cancer

Real-world (RW) use patterns, effectiveness, and tolerability of sacituzumab govitecan (SG) for second-line (2L) and later treatment of metastatic triple-negative breast cancer (mTNBC)

Breast cancer

Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study

Multiple Tumor Types

Picturing progression: A new role of whole slide imaging in comprehensive clinical genomic datasets

Lung cancer

Genomic landscape of patients with non-small cell lung cancer (NSCLC)

Breast cancer

Real-world treatment (Tx) patterns in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US)

Myelodysplastic syndrome

Real-world analysis of a large electronic medical record database of patients with higher-risk myelodysplastic syndromes (HR MDS): Treatment profiles, clinical effectiveness, and key adverse events

Breast cancer

Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US)

Breast cancer

Real-world outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) in 2L+ in the United States (US)

Acute Myeloid Leukemia

P572: Real-world management and outcomes for newly diagnosed AML patients initiating Venetoclax and hypomethylating agents in US community practice

Ovarian cancer

A real-world study of US patients with metastatic ovarian, fallopian tube, and peritoneal cancer (mOFPC) using integrated electronic health records (EHR) and claims datasets

Lung cancer

Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer

Breast cancer

Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer

Hodgkin’s lymphoma

Unfavorable early-stage Hodgkin lymphoma: assessment of patient characteristics in a real-world setting

Cervical cancer

Patient profiles, treatment patterns, and outcomes among persistent, recurrent, or metastatic cervical cancer patients under routine care in the United States

Cervical cancer

Treatment patterns and outcomes among locally advanced cervical cancer patients receiving concurrent chemoradiotherapy

Lung cancer

Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets

Ovarian cancer

Comparison of advanced ovarian cancer patients treated with or without bevacizumab in the US community oncology clinics

Acute Myeloid Leukemia

Real-world management and outcomes for newly diagnosed AML patients initiating Venetoclax and hypomethylating agents in US community practice

Lung cancer

Treatment outcomes in patients (pts) with advanced/metastatic non‑small cell lung cancer (NSCLC) harboring MET amplification as a secondary oncogenic driver

Lung cancer

Biomarker testing and treatment patterns in US patients (pts) with advanced/metastatic non‑small cell lung cancer (NSCLC) harboring MET amplification

Chronic Lymphocytic Leukemia

CO210 Real-World Effectiveness and Treatment Patterns of Venetoclax-Based Regimens Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated in Community Settings

Renal cell carcinoma

Real-world study on characteristics, post-nephrectomy journey, and outcomes of patients with early-stage renal cell carcinoma based on risk groups

other

Evaluating clinical trial inclusion/exclusion criteria from claims using generative artificial intelligence

Breast cancer

Electronic health record (EHR) and genomics-based machine learning (ML) to predict therapeutic effectiveness among patients with hormone-receptor positive (HR)+/HER2- advanced breast cancer (aBC)

Prostate cancer

Risk of Death Before and After Metastasis in High-Risk Localized and Locally Advanced Prostate Cancer Patients Undergoing Radical Prostatectomy or Radiotherapy as Primary Treatment in the United States: A Retrospective Study

Lung cancer

Assessment of electronic health record (EHR) –based machine learning (ML) in predicting risk of brain metastasis among patients with early-stage non–small-cell lung cancer (eNSCLC)

Bladder cancer

Identification of biomarkers for early progression in muscle invasive bladder cancer (MIBC) using real-world data

other

Digital trial solutions eScreening: software to rank patients by their predicted clinical trial eligibility using real-world data and machine learning

Myelodysplastic syndrome

A machine learning model to facilitate patient-level risk screening in myelodysplastic syndromes (MDS) patients in routine clinical practice

Lung cancer

Electronic health record (EHR)-based machine learning (ML) to predict disease recurrence after surgical resection of early-stage non-small cell lung cancer (eNSCLC)

Lung cancer

Real-world treatment patterns and clinical outcomes post standard of care (SOC) among patients (pts) with metastatic non-small cell lung cancer (mNSCLC) with and without actionable genomic alterations (AGAs) in the United States (US)

Lung cancer

LUMINATE 102: A real-world study on biomarker testing rates among patients with non-small cell lung cancer (NSCLC) across lines of therapy

Lung cancer

PP01.46 Real-world rebiopsy and biomarker retesting rates among patients with non-small cell lung cancer across patient demographics in the United States

Lung cancer

PP01.58 Real-world outcomes in patients with EGFR wildtype non-squamous locally advanced/metastatic NSCLC receiving second- or third-line docetaxel: Pooled analysis from LUMINATE-101

Lung cancer

Augmenting synthetic control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer

Lung cancer

Evaluation of patients with multiple EGFR genomic tests in the metastatic NSCLC setting

Lung cancer

Evaluation of treatment strategies for patients with stage IIIA non-small cell lung cancer in the immunotherapy era

Lung cancer

Efficacy of lurbinectedin in a clinical trial versus standard of care in a real-world comparator arm in relapsed/refractory small cell lung cancer patients

Lung cancer

Machine learning modeling of real-world primary resistance and hyperprogression in immune checkpoint inhibitor (ICI) treated advanced non-small cell lung cancer (aNSCLC) patients

Lung cancer

Disparities in timely treatment among lung cancer patients

Lung cancer

Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy

Multiple myeloma

Real-world treatment patterns and outcomes of daratumumab retreatment in multiple myeloma in the United States

Multiple myeloma

Treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma receiving ≥3 lines of therapy: A real-world evaluation in the United States

Colorectal cancer

Real-world outcomes among patients with metastatic colorectal cancer treated first line with bevacizumab-awwb

Acute Myeloid Leukemia

STREAMLINE - Retrospective cohort study of FLT3-mutated acute myeloid leukemia (AML): Real-world treatment patterns and clinical outcomes after first relapse or refractory (R/R) diagnosis

Lung cancer

Natural language processing-optimized case selection for real-world evidence studies

Breast cancer

Real-world outcomes among HER2-positive metastatic breast cancer patients treated with trastuzumab deruxtecan in the United States

Breast cancer

Unmet need in heavily pre-treated patients with HR+/HER2- metastatic breast cancer (mBC) in the US: a ConcertAI analysis

Lung cancer

Use of immunosuppressive drugs and the effectiveness of immune checkpoint inhibitor therapy among patients with advanced/metastatic non-small cell lung cancer in the United States

other

Outcomes among patients with mantle cell lymphoma post-covalent BTK inhibitor therapy in the United States: a real-world electronic medical records study

other

Outcomes for patients with mantle cell lymphoma post-covalent BTK inhibitor therapy in the United States and Japan: a study of two real-world databases

Chronic Lymphocytic Leukemia

Outcomes for patients with chronic lymphocytic leukemia (CLL) previously treated with both a covalent BTK and BCL2 inhibitor in the United States: A real-world database study

Cervical cancer

Real-world patient profiles, treatment patterns, and outcomes among recurrent, persistent, and metastatic cervical cancer patients

Classical Hodgkin’s lymphoma

Early-stage unfavorable Hodgkin lymphoma: Patient characteristics in real-world oncology data from the United States

Classical Hodgkin’s lymphoma

Treatment patterns and clinical outcomes among patients with relapsed/refractory classical Hodgkin's lymphoma

Renal cell carcinoma

Disease-free and overall survival outcomes for localized RCC patients by disease stage

Lung cancer

Treatment patterns and outcomes among patients with EGFR-mutant advanced NSCLC in the frontline and post-osimertinib settings

Lung cancer

Lurbinectedin vs an external control arm in patients with small cell lung cancer

Lung cancer

Disease-free survival (DFS) as a predictor of overall survival in completely reseacted early-stage non-small cell lung cancer (NSCLC)

Lung cancer

Treatment patterns, overall survival (OS), and disease-free survival (DFS) in early-stage non-small cell lung cancer (NSCLC) following complete resection

other

Racial disparities in newly diagnosed hematological malignancies in the United States during the COVID-19 pandemic, January 2020 to March 2021

Breast cancer

Identifying genetic factors of response and resistance to CDK4/6 inhibitors in metastatic HR+/HER2-breast cancer using real-world data

Prostate cancer

Impact of trial site selection on minority patient recruitment in prostate cancer trials

Lung cancer

Effect of COVID-19 vaccination status on adverse events and outcomes in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapies

other

Evaluating the impact of performance status criteria on minority eligibility for oncology clinical trials

Breast cancer

Comparison of DNA sequencing, immunohistochemistry, and in-situ hybridization techniques to determine HER2 status in metastatic breast cancer patients

other

Cohort optimizer, a software solution that uses real-world data and AI to optimize criteria of oncology trials

Breast cancer

Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) after prior treatment (tx) with FUL in patients (pts) with advanced breast cancer (ABC): A real-world (RW) analysis

Lung cancer

Identifying genetic factors for resistance and response to immune checkpoint inhibitors (ICIS) in advanced non-small cell lung cancer (aNSCLC) patients using real-world data

Breast cancer

Utilizing data visualization to identify survival and treatment differences between women with de novo and recurrent metastatic breast cancer

Breast cancer

Race differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer

Colorectal cancer

Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer

Colorectal cancer

Demographics and clinical characteristics of metastatic colorectal cancer patients treated with bevacizumab-awwb in real-world oncology clinics

Multiple tumor types

Identification of transgender people with cancer in electronic health records: recommendations based on CancerLinQ observations

Lung cancer

Impact of broadening trial eligibility criteria for patients with advanced non–small cell lung cancer: real-world analysis of select ASCO-Friends recommendations

Lung cancer

Real-world progression-free survival by timing of molecular profiling testing among metastatic non-small cell lung cancer patients in a community setting

Breast cancer

Demographics, clinical characteristics, and treatment patterns for patients with BRCA mutated, HER2-negative early stage breast cancer: a CancerLinQ® real-world US study

Lung cancer

Mild or moderate adverse events (AEs) and their management in patients receiving immune checkpoint inhibitors (ICIs) for advanced/metastatic non-small cell lung cancer (NSCLC) in the United States (US)

Multiple tumor types

Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: A machine learning approach

Lung cancer

Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer

Lung cancer

The Friends of Cancer Research real world data (RWD) collaboration pilot 2.0: methodological recommendations from oncology case studies

Lung cancer

Real-world overall survival using oncology electronic health record data: Friends of Cancer Research pilot

Other

The Friends of Cancer Research Real World Data (RWD) Pilot 2.0 Collaboration: Implementation of Standardized Methodological Approaches for Evaluation of Oncology RWD

Breast cancer

Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6i for HR+, HER2- MBC in the real world

Chronic Lymphocytic Leukemia

Outcomes for patients with chronic lymphocytic leukemia previously treated with a covalent BTK inhibitor and BCL2 inhibitor in the United States: a real-world database study

other

Outcomes for patients with mantle cell lymphoma post-covalent BTK inhibitor therapy in the United States and Japan: a study of two real-world databases

Breast cancer

Healthcare Resource Utilization and Cost Among Patients Treated for Early-Stage Triple-Negative Breast Cancer

Breast cancer

Real-World Treatment Patterns and Effectiveness Outcomes in Patients with Early-Stage Triple-Negative Breast Cancer

Multiple tumor types

Clinical and utilization outcomes associated with tumor mutational burden in a real-world pan-tumor population

Ovarian cancer

Demographic and clinical characteristics of advanced ovarian cancer patients treated with bevacizumab in real-world oncology clinics in the United States

Multiple tumor types

Real-world patterns on tumor mutation burden testing in a pan-tumor population

Lung cancer

Treatment effectiveness in a rare oncology indication: Lessons from an external control cohort study

Lung cancer

Non-interventional cohort study on patients with advanced non-small cell lung cancer harboring MET exon 14 skipping in the US

Multiple myeloma

Enhancing diversity in oncology clinical trials: Findings of a case study in improving black patient representation in a multiple myeloma trial

Multiple tumor types

Assessment of differences in demographic characteristics and clinical diagnoses among black and white oncology patients with COVID

Melanoma

Machine learning imputation of metastatic status from open claims in melanoma patients

Lung cancer

Algorithm to derive progression based lines of therapy from a real world non-small cell lung cancer (NSCLC) dataset

Prostate cancer

Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer in community oncology settings

Lung cancer

Trends in biomarker testing among advanced NSCLC patients in oncology practice settings in the US

Prostate cancer

Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings

Lung cancer

Real-world effectiveness of EGFR TKI first-line treatment of advanced EGFR mutation-positive non-small cell lung cancer in the US

Breast cancer

Treatment patterns and overall survival in HER2+ metastatic breast cancer at US community oncology practices

Breast cancer

Characterization of clinical symptoms by race among women with early stage, hormone receptor-positive breast cancer before starting chemotherapy

Breast cancer

Differences by race in patient-reported symptoms during chemotherapy among women with early-stage, hormone receptor-positive breast cancer

Colorectal cancer

Metastatic colorectal cancer patients treated with a biosimilar to bevacizumab in real world clinical setting

Colorectal cancer

Demographics and clinical characteristics of metastatic colorectal cancer patients treated with a biosimilar to bevacizumab

Lung cancer

Annual trends in opioid prescribing for patients with metastatic non-small cell lung cancer (mNSCLC): Cancerlinq data analysis, 2010 to 2017

Multiple tumor types

Identification of transgender people with cancer in electronic health records (EHR): Recommendations based on CancerLinQ observations

Acute Myeloid Leukemia

Streamline – Retrospective cohort study of relapsed or refractory (R/R) FLT3 mutated acute myeloid leukemia (AML): Real-world treatment, testing patterns, and outcomes

Lung cancer

Machine learning imputation of Eastern Cooperative Oncology Group performance status (ECOG PS) scores from data in CancerLinQ discovery

Lung cancer

Artificial intelligence model to predict slow progression for advanced non-small cell lung cancer (aNSCLC) patients receiving second-line therapies

Multiple tumor types

Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: A machine learning approach

Multiple tumor types

Cancer patient perspectives on sharing of medical records and mobile device data for research purposes

Lung cancer

Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC) patients: Analysis of real-world data

Breast cancer

Development of a prognostic factor index among women with HR+/HER2- metastatic breast cancer in a community oncology setting

Head and neck carcinoma

Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States

Breast cancer

Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer

Lung cancer

Clinical effectiveness outcomes and healthcare resource utilization of patients diagnosed with small cell lung cancer

Breast cancer

Locoregional recurrence in patients with early-stage triple-negative breast cancer receiving neoadjuvant systemic therapy: Patient characteristics and clinical outcomes

Hodgkin’s lymphoma

Real-world conditional survival analysis of patients with relapsed/refractory classical Hodgkin’s lymphoma in the US

Multiple tumor types

Tumor mutational burden (TMB) level and clinical outcomes in a real-world pan-tumor population

Hodgkin’s lymphoma

Treatment patterns and effectiveness outcomes in patients with relapsed/refractory classical Hodgkin’s lymphoma that received autologous and/or allogenic stem cell transplantation

Lung cancer

Progression-free survival, overall survival, and tumor response for patients diagnosed with small cell lung cancer who received first-line systemic therapy

Breast cancer

Assessing direct costs of treating metastatic triple-negative breast cancer in the USA

Breast cancer

Cost and healthcare resource utilization (HCRU) for patients receiving neoadjuvant therapy for early-stage triple-negative breast cancer (ESTNBC)

Hodgkin’s lymphoma

Healthcare resource utilization and cost in patients with relapsed/refractory classical Hodgkin’s lymphoma who received autologous stem cell transplantation in the US

Multiple tumor types

Real-world evidence on use of tumor mutation burden in a pan-tumor population.

Hodgkin’s lymphoma

Treatment patterns, healthcare resource utilization and cost among relapsed/refractory classical Hodgkin’s lymphoma patients in the US

Lung cancer

Treatment patterns, healthcare resource utilization and patient-reported outcomes for patients diagnosed with small cell lung cancer

Breast cancer

Development of an artificial intelligence model to dynamically predict metastatic recurrence of early-stage breast cancer patients

Breast cancer

Development of an algorithm using natural language processing to identify metastatic breast cancer patients from clinical notes

Lung cancer

Identifying non-small cell lung cancer patients from a cohort of heterogeneous lung cancer patients using boosted trees on electronic health records data

Multiple tumor types

Racial disparities in performance status among cancer patients at a community oncology practice

other

Using an ePRO tool to help meet quality metric reporting standards: screening for tobacco usage and falls

other

Performance of time to discontinuation and time to next treatment as proxy measures compared with direct observation of progression-free survival

other

Performance of time to discontinuation and time to next treatment as proxy measures of progression-free survival, overall and by treatment group

Breast cancer

Treatment patterns and clinical outcomes with palbociclib-based therapy received in US community oncology practices

Breast cancer

Patient and provider characteristics associated with first-line treatment of HR+/HER2- metastatic breast cancer patients in the US

Breast cancer

Occurrence of brain metastasis and treatment patterns among patients with HER2-positive metastatic breast cancer

Lung cancer

Real-world characteristics and outcomes of patients with advanced non-small cell lung cancer (aNSCLC) receiving immune checkpoint inhibitor

Multiple tumor types

Characteristics of patients receiving immune checkpoint inhibitors (ICI) in ASCO’s CancerLinQ

Multiple tumor types

Real-world prevalence of autoimmune disease (AD) among patients (pts) receiving immune checkpoint inhibitors (ICI) in ASCO’s CancerLinQ database

Lung cancer

Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs)

Lung cancer

Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis

Acute Myeloid Leukemia

Streamline - study of relapse or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) using electronic medical records (EMR): first analysis from a multicenter, retrospective cohort study

Breast cancer

Real-world effectiveness of fulvestrant monotherapy as first endocrine treatment in patients with metastatic breast cancer

Breast cancer

Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings

Lung cancer

Real-world outcomes in patients with unresected stage III non-small cell lung cancer

Lung cancer

Real-world treatment patterns among patients with unresected stage III non-small cell lung cancer

Colorectal cancer

Treatment patterns and outcomes in patients with KRAS wild-type metastatic colorectal cancer treated in first line with bevacizumab- or cetuximab-containing regimens

Colorectal cancer

Progression-free survival in patients receiving chemotherapy alone (C) or chemotherapy with bevacizumab (CB) for first-line treatment of KRAS mutant metastatic colorectal cancer in community oncology settings

Breast cancer

Real-world outcomes in patients receiving neoadjuvant chemotherapy for early-stage triple-negative breast cancer

Breast cancer

Patient characteristics and real-world treatment patterns in patients with early-stage triple-negative breast cancer receiving neoadjuvant chemotherapy

Breast cancer

Using artificial intelligence to improve capture of metastatic breast cancer (BC) status in electronic health records (EHR)

Lung cancer

Development of an artificial intelligence model to predict survival at specific time intervals for lung cancer patients

other

Capturing patient advance directives status in a community oncology practice using an electronic patient-reported outcomes (ePRO) system

other

Using an ePRO tool to help meet quality metrics in a community oncology practice

Breast cancer

THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer

Breast cancer

A qualitative exploration of race-based differences in social support needs of diverse women with breast cancer on adjuvant therapy

Multiple tumor types

Effect of pegfilgrastim on-body injector (OBI) on cancer care: A real-world health system and interrupted time series analysis

Lung cancer

Clinical outcomes among patients with unresected stage III non-small cell lung cancer (NSCLC) in a real-world setting

Head and neck carcinoma

Effectiveness outcomes in patients with recurrent or refractory head and neck cancers: retrospective analysis of data from a community oncology database

Bladder cancer

Treatment patterns and outcomes in stage IV bladder cancer in a community oncology setting: 2008-2015

Lung cancer

Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study

Head and neck carcinoma

Patient characteristics and costs in recurrent or refractory head and neck cancer: retrospective analysis of a community oncology database

Lung cancer

Understanding health-related quality of life (HRQoL) in unresected stage III non-small cell lung cancer (NSCLC)

Lung cancer

Real-world treatment patterns among patients with unresected stage III non-small cell lung cancer (NSCLC)

Other

Pretreatment costs of care and time to initial treatment for patients with cancer of unknown primary

Multiple tumor types

Impacts of time spent on rituximab infusion on patient satisfaction, stress, employment, and caregiver burden

Multiple tumor types

Time spent on rituximab infusion and its impact on patient and caregiver burden

Lung cancer

Effect of brain metastasis on patient-reported outcomes in advanced NSCLC treated in real-world community oncology settings

Neuroendocrine tumors

Treatment outcomes in patients with metastatic neuroendocrine tumors: a retrospective analysis of a community oncology database

Breast cancer

Outcomes among metastatic breast cancer patients with characteristics that confer a less favorable prognosis

Head and neck carcinoma

Progression-free survival and overall survival in advanced squamous cell carcinoma of head and neck (SCCHN): retrospective analysis of a community oncology database

Breast cancer

Real-world effectiveness outcomes by race in patients with metastatic triple negative breast cancer

Breast cancer

Assessing the real-world cost of care in patients with metastatic triple negative breast cancer (mTNBC) in the United States

Breast cancer

Artificial intelligence methods to predict chemotherapy-induced neutropenia in breast cancer patients

Renal cell carcinoma

Patient-reported outcomes among those taking pazopanib for metastatic renal cell carcinoma (mRCC) in a community oncology setting

Renal cell carcinoma

Patient reported outcomes in metastatic renal cell carcinoma patients receiving pazopanib in a community oncology setting

Breast cancer

Real-world treatment patterns and clinical outcomes with palbociclib combination therapy received in US community oncology practices

Breast cancer

Real-world treatment patterns and clinical outcomes stratified by age, in women with HR+/HER2- advanced/metastatic breast cancer receiving palbociclib combination therapy

Breast cancer

Real-world clinical outcomes in BRCA-positive metastatic breast cancer patients treated in the community oncology setting

Head and neck carcinoma

Progression-free survival in advanced head and neck cancer: retrospective analysis of a community oncology database

Bladder cancer

Treatment patterns and outcomes in metastatic bladder cancer in community oncology settings

Lung cancer

Health care cost in patients with advanced non-small cell lung cancer and disease progression on targeted treatment in a real-world setting

Breast cancer

Health resource utilization and costs in BRCA-positive metastatic breast cancer patients treated in the community oncology setting

Breast cancer

Characteristics of patients treated with fulvestrant as first hormonal therapy for metastatic breast cancer in a real world setting

Lung cancer

Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study

Lung cancer

Analysis of the psychological impact of cancer-related symptoms on patients with non-small cell lung cancer

other

Maximizing the utility of real-world evidence: integration of structured electronic medical record (EMR) data, unstructured EMR data, and billing data for economics and outcomes research in oncology

Breast cancer

Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer

Head and neck carcinoma

Patient characteristics and costs in advanced head and neck cancer: retrospective analysis of a community oncology database

Other

Clinical and health economic burden of attempted primary cancer site identification in patients presenting with cancer of unknown primary

Lung cancer

Effectiveness outcomes in patients with advanced NSCLC treated in real world community oncology settings: results from a prospective medical record registry study

Colorectal cancer

Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA

Colorectal cancer

Treatment patterns and outcomes in patients with KRAS wild type metastatic colorectal cancer (WTMCRC) treated in first line with bevacizumab (B) or cetuximab (C) containing regimens

Lung cancer

Impact of disease progression on patient reported outcomes in advanced NSCLC: evidence from patients treated in real world community oncology settings

Lung cancer

Effect of brain metastasis on patient reported outcomes in advanced NSCLC treated in real world community oncology settings

Neuroendocrine tumors

Treatment outcomes in patients with metastatic neuroendocrine tumors: retrospective analysis of a community oncology database

Breast cancer

The impact of extended endocrine therapy on symptom burden and health-related quality of life in patients with early-stage breast cancer (ESBC)

Melanoma

US burden of illness associated with adjuvant therapy for stage I-III melanoma

Lung cancer

Treatment patterns and health resource utilization among patients diagnosed with early stage resected non-small cell lung cancer at US community oncology practices

Neuroendocrine tumors

Treatment patterns and outcomes in metastatic neuroendocrine tumors: results from a retrospective community oncology database

other

Maximizing the utility of real world evidence: integration of structured EMR data, unstructured EMR data, and billing data for economics and outcomes research in oncology

Multiple myeloma

Real-world impact of treatment-induced peripheral neuropathy of patient-reported outcomes in patients with multiple myeloma in the United States

Multiple myeloma

Real-world impact of treatment-induced peripheral neuropathy of patient-reported outcomes in patients with multiple myeloma in the United States

Renal cell carcinoma

Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice

Melanoma

Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice

Breast cancer

Early treatment discontinuation and switching in first-line metastatic breast cancer: the role of patient reported symptom burden

Lung cancer

Treatment patterns and baseline characteristics of a prospective cohort of patients with advanced NSCLC treated in real world community oncology settings

Lung cancer

Real-world treatment patterns and health resource utilization among patients diagnosed with early stage resected non-small cell lung cancer (NSCLC) at community oncology practices in the US

Multiple myeloma

Association of treatment induced peripheral neuropathy with treatment patterns and outcomes in patients with newly diagnosed multiple myeloma

Renal cell carcinoma

Use of “Real world” data to describe adverse events for the treatment of metastatic renal cell carcinoma in routine clinical practice

Renal cell carcinoma

Real-world outcomes in metastatic renal cell carcinoma: insights from a joint community-academic registry

Renal cell carcinoma

Clinical trial subjects compared to patients treated in "real world" practice: generalizability of renal cell carcinoma trials

Prostate cancer

Treatment patterns and clinical effectiveness in metastatic castrate resistant prostate cancer after first-line docetaxel

Breast cancer

Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer

Multiple tumor types

Willingness to pay for preventing chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancer

Pancreatic cancer

The association of skin rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting

Breast cancer

Early treatment discontinuation and switching in 1st line metastatic breast cancer: impact of symptom burden in a real world sample

Breast cancer

Real world symptom burden and early treatment discontinuation in 1st line metastatic breast cancer

Basal cell carcinoma

Treatment patterns and clinical characteristics of patients with advanced basal cell carcinoma in the community oncology setting

Colorectal cancer

Predicting risk of chemotherapy-induced side effects in patients with colon cancer with single-nucleotide polymorphism (SNP) Bayesian networks (BNs)

Multiple tumor types

Use of a validated assessment tool demonstrates the frequency of patient-experienced, regimen-related side effects associated with the treatment of common solid tumors

Multiple tumor types

Anemia-related costs and adverse event rates in cancer patients who do not respond to erythropoietin stimulating agents

Colorectal cancer

KRAS testing of mCRC patients in a community-based oncology setting

Breast cancer

Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases

Multiple myeloma

Association of treatment induced peripheral neuropathy (TIPN) with treatment patterns and outcomes in patients with newly diagnosed multiple myeloma

Renal cell carcinoma

Adverse events among patient treated for metastatic renal cell carcinoma (mRCC): data from a real world, multicenter registry

Renal cell carcinoma

Adverse events (AEs) by age: data from a real world, multicenter registry of patients treated for metastatic renal cell carcinoma (mRCC)

Renal cell carcinoma

“Real world” treatment of metastatic renal cell carcinoma in a joint community- academic cohort: progression-free survival over three lines of therapy

Prostate cancer

Community oncology treatment patterns and clinical effectiveness in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed after docetaxel

Colorectal cancer

Using text mining of electronic medical records to identify KRAS testing status in mCRC patients

Gastric

Treatment patterns and outcomes in metastatic gastric cancer in the community oncology setting

Colorectal cancer

Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer

Basal cell carcinoma

Treatment patterns and clinical characteristics of patients with advanced basal cell carcinoma (aBCC) in the community oncology setting

Renal cell carcinoma

Outcomes of “real world” treatment for metastatic renal cell carcinoma (mRCC)

Multiple tumor types

Willingness to pay to prevent chemotherapy induced nausea and vomiting

Multiple tumor types

Cancer patient preferences and willingness to pay for preventing chemotherapy induced nausea and vomiting in the U.S.

Follicular lymphoma

Symptom burden and quality of life in patients with follicular lymphoma undergoing maintenance treatment with rituximab compared with observation

Breast cancer

Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients

Melanoma

Treatment patterns among patients with metastatic melanoma treated in the community oncology setting

Multiple tumor types

The Patient Care Monitor-Neutropenia Index: development, reliability, and validity of a measure for chemotherapy-induced neutropenia

Renal cell carcinoma

“Real world” treatment of metastatic renal cell carcinoma (mRCC) in community and academic settings

Breast cancer

Symptom burden declines when breast cancer patients treated with adjuvant trastuzumab / combination chemotherapy regimens enter trastuzumab monotherapy follow-up

Breast cancer

Testing and treatment patterns in HER2+ breast cancer patients in the adjuvant setting

Lung cancer

Treatment patterns, medical resource use, and costs associated with second line treatment of non small cell lung cancer

Lung cancer

Engagement of lung cancer patients in quality of life assessments administered by tablet computer as a routine part of clinical care

Multiple tumor types

Use of the Patient Care Monitor to screen for depression in adult cancer patients interviewed with the structured clinical interview for DSM-IV

Multiple tumor types

Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients

Breast cancer

A retrospective study of quality of life in a community sample of patients with early stage breast cancer

Breast cancer

The effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients

Follicular lymphoma

Symptom burden in patients with follicular lymphoma undergoing maintenance treatment with Rituxan compared with observation

Lung cancer

Psychosocial impact of cancer related symptoms among patients with lung cancer

Multiple tumor types

The relation of trouble sleeping, depressed mood, pain and fatigue in patients with cancer

Multiple tumor types

Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology

other

Considerations in the use of secondary data sources for oncology research

Breast cancer

Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer

Multiple tumor types

Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: Assessment of clinical consequences

Multiple tumor types

Relation of sleep disturbance, depression, pain, and fatigue in patients with cancer

Multiple tumor types

Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data

Colorectal cancer

Irinotecan is associated with greater symptom burden than oxaliplatin in metastatic colorectal cancer patients (mCRC) in community oncology

Multiple tumor types

Prevalence of insomnia and associated symptoms in patients with cancer

Colorectal cancer

Symptom burden for patients with metastatic colorectal cancer treated with first-line FOLFOX or FOLFIRI with and without bevacizumab in the community setting

Breast cancer

Practice patterns of community based adjuvant hormonal therapy (AHT) in early stage breast cancer (ESBC)

Multiple tumor types

Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation

Colorectal cancer

Patient survey of the impact of toxicities with FOLFOX + Bevacizumab (BV) in 1st line metastatic colorectal cancer (MCRC) in the community oncology setting

Multiple tumor types

The Cancer Care Monitor: Psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients

Cervical cancer

Characteristics, treatment patterns, and outcomes in patients with high-risk locally advanced cervical cancer

Breast cancer

Disparities in genetic testing patterns and positivity among patients with breast cancer in the CancerLINQ real-world oncology database

Lung cancer

Patient characteristics, treatment patterns, and factors of biomarker testing among patients with advanced non-small cell lung cancer (ANSCLC) in the US, 2012-2020

Prostate cancer

Association of clinical trial enrollment and mortality amongst patients with advanced prostate cancer

Prostate cancer

Variation of hormonal agent usage with postoperative radiation therapy: Results from a population based cohort of prostate cancer patients in community oncology practices

Bladder cancer

Real-world treatment patterns and sequencing in patients with locally advanced or metastatic urothelial cancer (la/mUC) in the US

Other

Vital status ascertainment in cancerlinq discovery (CLQD): Improvement in mortality capture with a supplemental data source

Lung Cancer

Overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) patients treated with frontline chemotherapy or immunotherapy by comorbidity: A real-world data (RWD) collaboration

Lung cancer

Treatment trends with immune checkpoint inhibitor (ICI) therapy in older adults with lung cancer

Ovarian cancer

Low rates of BRCA1 and BRCA2 testing for patients with ovarian cancer in ASCO's CancerLinQ, a real-world database

Lung cancer

Associations between biomarker testing and characteristics of patients with metastatic non–small cell lung cancer (mNSCLC): An analysis of CancerLinQ Discovery (CLQD) data

Lung cancer

Molecular testing and patterns of treatment in NSCLC patients: An IASLC analysis of ASCO CancerLinQ Discovery data

Breast cancer

The survival benefit of anti-HER2 treatment in the management of small (T1mic, T1a, T1b, T1c), node-negative HER2+ breast cancer

Prostate cancer

Diagnosed with advanced prostate cancer: A population-based cohort from national oncology practices

Lung cancer

Characterizing node-negative non-small cell lung cancer patients with similarity networks: A CancerLinQ Discovery analysis

Breast cancer

The relationship between treatment intensity and characteristics of patients with early stage breast cancer

Other

Impact of curated data on electronic quality measure capture rates within CancerLinQ

Other

Disproportionate impact of COVID-19 disease among racial and ethnic minorities in the U.S. cancer population as seen in CancerLinQ Discovery data

Breast cancer

Real-world clinical outcomes of patients with BRCA-mutated (BRCAm) HER2-negative metastatic breast cancer: A CancerLinQ® study

other

Treatment patterns and outcomes of hepatocellular carcinoma (HCC) patients (pts) in the CancerLinQ Research Database (CLQ)

Other

Care at the end of life during the COVID-19 pandemic: A CancerLinQ Discovery® (CLQD) Analysis

Breast cancer

Development of a breast cancer-specific prognostic tool using CancerLinQ Discovery

Breast cancer

Survival in the real world: A national analysis of patients treated for early stage breast cancer

Lung cancer

Natural history and real-world treatment outcomes for NSCLC patients with EGFR exon 20 insertion mutation: An IASLC- ASCO CancerLinQ study

Lung cancer

Treatment patterns and characteristics in the second and third-line therapy setting for real-world small cell lung cancer patients

Lung cancer

Overall survival throughout treatment course among patients diagnosed with small cell lung cancer

Other

Disruptions to US medical oncology care during the COVID-19 pandemic: CancerLinQ Discovery® (CLQD) analysis

Lung cancer

773 - Evaluating clinical features and prognostic factors associated with response to immune checkpoint blockade in mNSCLC patients

Lung cancer

66P - EGFR testing patterns and survival in stage I‒III non-small cell lung cancer (NSCLC): analysis using the CancerLinQ Discovery® (CLQD) database

Lung cancer

Long term survival outcomes in NSCLC patients with targeted therapy and immunotherapy: An IASLC analysis of ASCO CancerLinQ Discovery data

Lung cancer

935P - Demographics, clinical characteristics, treatment patterns and clinical outcomes of patients with stages I-III resected NSCLC without known EGFR mutations

Breast cancer

Real world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer

Multiple myeloma

Secondary primary malignancies (SPMs) in adolescent and young adults (AYAs) with multiple myeloma (MM): An ASCO CancerLinQ analysis

Multiple myeloma

Survival of patients with multiple myeloma diagnosed with second primary malignancies: An ASCO CancerLinQ analysis

Multiple tumor types

Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals

Kidney

Real-world evidence shows no survival advantage with contemporary first-line strategies in papillary renal cell carcinoma: A call for randomized trials

Breast Cancer

Data stacking of RWD from two EMR databases in the United States using tokenization

Colorectal cancer

Epidemiology of MET gene mRNA expression in metastatic colorectal cancer: Analyses of a real-world clinicogenomic database

Multiple tumor types

Comorbidity assessment using integrated EHR and claims in a national oncology database 

Bladder Cancer

Integrated multi-setting real-world data to advance bladder cancer evidence generation

Prostate Cancer

The value of integrating multi-care settings real world data for understanding prostate cancer management

Lung cancer

Optimizing the identification and classification of non-small cell lung cancer (NSCLC): Validation and implementation of a patient cohort algorithm in claims databases

Multiple tumor types

Real-world use of accelerated approval oncology drugs subsequently withdrawn in the United States

Lung Cancer

Effect of IFNG Expression Levels on Real-World Survival Outcomes in Patients With Metastatic Non-Small Cell Lung Cancer Receiving Immunotherapy

Lung Cancer

Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States

Pancreatic Cancer

Predictive Modeling for Survival Outcomes in Surgically Resected Pancreatic Ductal Adenocarcinoma: A Comprehensive Machine Learning Approach Using Real-World Data

Renal Cancer

SUNNIFORECAST Trial Design Supported by Real-World Data in Papillary Renal Cell Carcinoma

Bladder Cancer

Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice

Lung Cancer

A United States-based real-world study on biomarker testing and rebiopsy rates among patients with non-small cell lung cancer across lines of therapy

Breast Cancer

Quantification of information gained by linking claims data to an electronic health record cohort of patients with metastatic breast cancer

Lung Cancer

Real-world treatment patterns among advanced non-small cell lung cancer patients in the US

AML

Real-world characteristics, treatment modifications, and outcomes for patients with acute myeloid leukemia (AML) receiving hypomethylating agents (HMA) + venetoclax (VEN) as first-line treatment (1L)

Other

Using AI methodology to stack and harmonize two U.S. EMR databases

Other

Harmonizing Logical Observation Identifiers Names and Codes (LOINC) Codes and Units in Real-World Oncology Data: Method Development and Evaluation

Gastric

Biomarker prevalence in US patients with gastric/gastroesophageal junction adenocarcinoma (GEA) from real-world data

Pancreatic Cancer

Predictive modeling for survival outcomes in surgically resected pancreatic ductal adenocarcinoma: A comprehensive machine learning approach using real-world data

Melanoma

Predicting real-world overall survival in advanced melanoma using machine learning

Lung Cancer

Seizure related 6 homolog (SEZ6) expression pattern and prognostic impact in a real-world cohort of patients with small cell lung cancer

Prostate Cancer

Real-world prostate-specific antigen (PSA) response with darolutamide or abiraterone in metastatic hormone-sensitive prostate cancer (mHSPC) triplet therapy

Colorectal Cancer

Real-world characteristics and outcomes of patients with third-line or later metastatic colorectal cancer: Magnetic-101 study results

Breast Cancer

Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer

Breast Cancer

Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HR+/HER2- early breast cancer

Lung Cancer

Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous non-small cell lung cancer: pooled analysis from project LUMINATE-101

Breast Cancer

Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: A United States Electronic Health Records database analysis

Prostate Cancer

Real-world treatment patterns and survival in people with metastatic castration-resistant prostate cancer following metastatic hormone-sensitive disease between 2020 and 2023 in the United States

Lymphoma

Real-world monotherapy and combination usage of mogamulizumab among patients with mycosis fungoides or Sézary syndrome in the United States

Lung Cancer

Real-world EGFR testing and adjuvant treatment patterns among patients with resected early-stage non-small cell lung cancer (NSCLC) in the United States

Renal Cancer

F3 Shifting treatment patterns in chromophobe renal cell carcinoma: A U.S. real-world data analysis

Lung Cancer

Leveraging NSCLC foundation models to predict biomarker testing pattern

Colorectal Cancer

A multi-agent system for automated identification of competitive clinical trials in colorectal cancer

Colorectal Cancer

Real-world clinical outcomes among metastatic colorectal cancer (mCRC) patients with liver metastases who received trifluridine/tipiracil (FTD/TPI) or FTD/TPI + bevacizumab (FTD/TPI+bev) combination therapy

Colorectal Cancer

Clinical Outcomes of Patients With Metastatic Colorectal Cancer Treated With Trifluridine-Tipiracil + Bevacizumab by Performance Status

Colorectal Cancer

Trifluridine–Tipiracil with and without Bevacizumab in Colorectal Cancer

Prostate Cancer

Androgen-receptor pathway inhibitors triplet therapy (ARAAT): Real-world outcomes in metastatic hormone-sensitive prostate cancer

Bladder cancer

Real-World Treatment Patterns, Recurrence, and Overall Survival of Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy in U.S. Oncology Practice

Myelodysplastic syndrome

Real-World Study of Use Patterns and Clinical Outcomes for Patients with Myelodysplastic Syndrome Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents

Breast Cancer

Exploration of Real-World Outcomes in Patients with Previously Treated HR+/HER2- and Triple Negative Metastatic Breast Cancer

Lung Cancer

Impact of Real-World Response to First-Line Immunotherapy and Chemotherapy on Subsequent Treatment Outcomes in Patients With Advanced or Metastatic Non–Small Cell Lung Cancer

Prostate Cancer

Pathway-Level Molecular Evolution and Composite Molecular Genomic Risk following Lu-177-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

Utilization of Liquid Biopsy in Metastatic Castrate Resistant Prostate Cancer (mCRPC): Patient Characteristics, Treatment Selection, and Mutational Status

Prostate Cancer

Molecular Evolution and Resistance Mechanisms after Lu-177-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer

Bladder Cancer

Subsequent Treatment Patterns and Outcomes Among Patients with Muscle Invasive Bladder Cancer (MIBC) Receiving Neoadjuvant Treatments: A Real-World Data Analysis

Prostate Cancer

Survival Outcomes of Cabazitaxel or Subsequent Androgen Receptor Pathway Inhibitor (ARPI) in Post-Docetaxel/ARPI Metastatic Castration-Resistant Prostate Cancer

Lung Cancer

A deep learning-based multimodal integration framework for clinical outcome prediction

Prostate Cancer

Real-World Shift Toward Triplet Therapy in Metastatic Prostate Cancer Is Associated With Improved PSA Responses and Overall Survival vs Docetaxel Doublet

Ovarian Cancer

Epidemiology of folate receptor alpha expression in ovarian cancer by age, race/ethnicity, and histotype in a real-world, US-based clinicogenomic database

Colorectal Cancer

Multi-modal real-world data uncovers predictors of clinical response to TOP1i and optimizes ADC strategies in colorectal cancer

Lung Cancer

Prevalence and distinct biological programs of small cell lung cancer molecular subtypes revealed by real-world clinico-genomics database

Breast Cancer

Comparing LLM-based to expert-curated extraction for biomarker attributes in lung and breast cancer

Gastric

Real-world treatment patterns and clinical outcomes among cholangiocarcinoma patients treated with futibatinib or pemigatinib

Renal Cancer

Biomarker-defined outcomes in metastatic clear cell renal cell carcinoma (mccRCC) receiving first-line (1L) immune checkpoint inhibitor-based therapy

Lung Cancer

Real-world effectiveness of MET inhibitors versus immunotherapy ± chemotherapy in 1L for patients with MET exon 14 skipping mutations in non-small cell lung cancer

Other

AI-enabled clinical trial framework for end-to-end site recommendation and enrollment projection

Other

Research, evidence, and application

Content topic ⌄

Content format ⌄

Therapeutic area ⌄

Developing a digital twin framework for colorectal cancer outcome prediction and robust clinical trial simulation

STREAMLINE - Retrospective cohort study of FMS-like tyrosine kinase 3-mutated acute myeloid leukemia: Real-world treatment patterns and clinical outcomes of patients in first relapse or refractory diagnosis

Patients with advanced non-small cell lung cancer harboring MET alterations: A descriptive cohort study

(PB2488) Chart review study on the real-world cytopenia management of patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents

(PB2779) Chart review study on dose modifications of patients with myelodysplastic syndrome treated with hypomethylating agents

Comparison of outcomes for patients (pts) with R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with Bruton tyrosine kinase inhibitor (BTKi) and venetoclax from the TRANSCEND CLL 004 study versus a matched cohort of real-world (RW) pts

Identification of predictive subphenotypes for clinical outcomes using real world data and machine learning

Treatment patterns and survival by race among men with metastatic castration-resistant prostate cancer (mCRPC) in the United States: A US electronic medical record database 2020-2023

Real-world treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC) who previously progressed from metastatic hormone-sensitive prostate cancer (mHSPC) between 2020 to 2023 in the United States

Biomarker testing and patterns of treatment in NSCLC patients: An IASLC analysis of ASCO CancerLinQ Discovery data

Practice patterns and outcomes of conventional versus split-dose cisplatin in neoadjuvant ddMVAC in bladder cancer

Survival outcomes among metastatic castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitor and docetaxel

Clinical use and outcomes of androgen-receptor pathway inhibitors triplet therapy for metastatic hormone-sensitive prostate cancer (ARAAT)

Survival impact of adjuvant chemotherapy regimens for small (T1mi/a/b), node-negative (pN0), triple-negative breast cancer (TNBC)

Leveraging real-world data sources for clinical oncology research: A review of studies published in ASCO publications

Analysis of ASCO clinical guidelines authorship and institutional representation using HemOnc.org

Real-world side effects of targeted therapies: High-throughput association studies leveraging the CancerLinq Discovery lung cancer database

CO125: Adjusted comparison of amivantamab in combination with carboplatin plus pemetrexed from the PAPILLON study versus US real-world frontline treatments in patients with advanced NSCLC harboring EGFR exon 20 insertions

HSD64: Real-world adjuvant nivolumab utilization in surgically treated muscle-invasive bladder cancer patients within U.S. community oncology practice

Recurrence and its association with overall survival (OS) in muscle-invasive bladder cancer (MIBC) patients undergoing radical cystectomy (RC): A real-world analysis

Post-metastasis survival of patients with high-risk localized and locally advanced prostate cancer undergoing primary treatment in the United States: A retrospective study

Prognostic score models for acquired resistance to frontline anti-programmed cell death protein 1/programmed death-ligand 1 therapy in metastatic non-small-cell lung cancer

P32: Oncology trial emulation using real-world electronic health record data: Results of the Coalition to Advance Real-World Evidence through Randomized Controlled Trial Emulation (CARE) initiative

Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study

Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: A real-world evidence study

Epidemiology of MET gene mRNA expression in metastatic colorectal cancer: Analyses of a real-world clinicogenomic database

Patterns of concurrent chemotherapy selection in US patients undergoing trimodality therapy for muscle-invasive bladder cancer

Real world evidence comparison of first-line (1L) immune-oncology(IO)/tyrosine kinase inhibitor (TKI) vs. IO/IO combination therapy in renal cell carcinoma (RCC)

6638 / 19 - Identifying cancer germline variants associated with patient prognosis and response by applying clinico-genomics data

3395 / 15 - Investigating clinical features and molecular mechanisms of long-term response and acquired resistance to immunotherapy in non-small cell lung cancer by applying real-world-data

Survival outcomes of apalutamide as a starting treatment: Impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS)

Pediatric cancer in the United States: A comparison of three data sources

656P Real-world (RW) frontline (1L) treatments (Txs) in patients (Pts) with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EFGR) exon 20 insertions (exon20ins) and adjusted comparisons versus PAPILLON study

The value of integrating urology and oncology real-world data for understanding prostate cancer management

Real-world use of accelerated approval oncology drugs subsequently withdrawn in the United States

Comparing traditional NLP methods and LLM-based extraction for identifying biomarkers in lung cancer

Electronic health records (EHR)-based machine learning (ML) approach to predict risk of progression to metastatic melanoma after initial diagnosis

Machine learning model to forecast patient availability for oncology clinical trials

RWD116: Training and validation of CARAai™: A multi LLM platform and data model to address oncology-specific challenges in clinical data extraction

EPH131: Estimating US cancer prevalence with community oncology EHR-based datasets via national benchmarks from SEER and NPCR

Behavior of test specificity under an imperfect gold standard: Findings from a simulation study and analysis of real-world oncology data

Real-world clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with trifluridine-tipiracil + bevacizumab by performance status

Real-world patient characteristics and treatment patterns among cholangiocarcinoma patients treated with FGFR inhibitors

Leveraging large language models to drive efficiency in clinical trial simulation

Real-world clinical outcomes of trifluridine-tipiracil monotherapy (FTD-TPI) and FTD-TPI + bevacizumab combination therapy (FTD-TPI+bev) in 639 black patients (pts) with metastatic colorectal cancer (mCRC)

Real-world clinical outcomes of patients (pts) with metastatic colorectal cancer (mCRC) who received trifluridine-tipiracil (FTD-TPI) monotherapy or FTD-TPI + bevacizumab (FTD-TPI+bev) combination therapy

Real-world effectiveness of frontline treatments among patients with chronic lymphocytic leukemia: Results from ConcertAI

Biomarkers of response in patients with gastric/gastroesophageal junction adenocarcinoma (GEA) treated with telisotuzumab adizutecan

Folate receptor alpha (FRα; FOLR1) expression and persistence in ovarian cancer in clinical trial samples and real-world patient cohort

Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors

Racial disparities in clinical trial enrollment among patients diagnosed with prostate cancer: A population-based cohort of oncology practices

Clinical characteristics and treatment of patients with small cell prostate cancer: Analysis of a real-world cohort from an oncology database

P1-09-09: Disparities in second breast cancer events and survival persist despite optimal treatment in hormone-receptor positive breast cancer: Analysis of the real-world ASCO CancerLinQ dataset

P3-03-12: Social determinants of health (SDOH) and Z code utilization among patients with breast cancer (BC)

P1-08-09: Real-world outcomes comparing 3-monthly with monthly goserelin implant in premenopausal women with breast cancer

Evaluation of treatment strategies for patients with stage IIIA non-small cell lung cancer in the immunotherapy era

Real-world treatment and clinical outcomes in patients with metastatic castration-resistant prostate cancer treated with olaparib in the United States

5189 Real-world use patterns and clinical outcomes for myelodysplastic syndrome patients initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents

4437 Real-world treatment patterns in patients with mycosis fungoides or Sezary syndrome treated with mogamulizumab in the United States: A retrospective database analysis

4623 Mutations in the Bruton tyrosine kinase (BTK) gene in patients with chronic lymphocytic leukemia (CLL) receiving BTK inhibitors (BTKis)

Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

EP.11A.08 Real-world comparative effectiveness in advanced NSCLC and high PD-L1 with 1L immune checkpoint inhibitors ± chemotherapy

Real-world clinical outcomes among patients with non-squamous advanced non-small cell lung cancer (aNSCLC) treated with docetaxel-based regimens post initial standard of care (SOC) in the United States

245P - Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis

1303P - METPRO: Evaluating prognostic value of c-Met protein overexpression and concurrent biomarker presence

1352P - Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy

Calibrating observational health record data against a randomized trial

Emulations of oncology trials using real-world data: A systematic literature review

Real-world treatment patterns and outcomes in patients with HR+/HER2− metastatic breast cancer treated with chemotherapy in the United States

Treatment intensification in metastatic hormone-sensitive prostate cancer: An analysis of real-world practice patterns from the CancerLinQ Database

RWD23 Addition of open administrative claims significantly improves capture of mortality in electronic health record (EHR) - focused real-world data (RWD)

Evaluation of real-world tumor response derived from electronic health record data sources: A feasibility analysis in mNSCLC patients treated with chemotherapy

194: Immune-related adverse events of anti-PD-(L)1 immunotherapy with and without chemotherapy in patients with advanced non-small cell lung cancer: A real-world evidence study

1361: Quantification of information gained by linking claims data to an EHR cohort of US metastatic breast cancer (mBC) patients

435: Identifying the period of heightened risk for adrenal insufficiency in patients with advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors

1433: Pediatric cancer in the United States: A comparison of two data sources